BioMark would like to introduce and welcome 2 new members to its scientific advisory board. The new members are:

• Dr. Samudra Dissanayake, Director Strategic Initiatives and Business Development Health-Tech-Connex
  Dr. Dissanayake has been an important contributor in the development of BioMark’s technology platform for cancer screening, response to treatment and cancer treatment. Dr. Dissanayake role would be to advise the management team on how to develop critical relationships with agencies and principal investigators both in USA and Canada.
• Dr. Horacio Bach, PhD, Adjunct Professor, Faculty Manager of IIRC Antibody Engineering and Proteomics Facilities, Department of Medicine, Div. of Infectious Diseases, University of British Columbia
  Dr. Bach’s expertise would greatly increases BioMark’s confidence in internalization studies related to an enzyme of interest, shed better understanding on mechanism of action and to conduct detailed receptor studies prior to commencing in vivo studies for select BioMark therapeutic drug candidates.